Our company

The Company's business model capitalizes on inventions and technology from which profits are created through licensing. MSI is dedicated to earning profit for its 8,600 shareholders by identifying, supporting, patenting and marketing technical innovation by harvesting top technology talent to bring game-changing product to the market.

We emphasize novel technology in the Nanomedicine space with the potential to be disruptive and the ability to establish sustainable businesses.

We are "patient capital" with experienced business building partners who bring the perspective of merchant bankers, not venture capitalists. Our approach to assist scientists to commercialize their work is by providing a forum within which the commercialization process is fostered through partnerships with existing companies (Fortune/1000 or larger). The entrepreneurial scientists and engineers who join us create personal success and wealth on an accelerated basis by virtue of ownership of publicly traded Manhattan Scientifics shares (OTC QB: MHTX).


Technology : Advenced Materials

Advanced Materials

Manhattan Scientifics has acquired the exclusive rights to the key patents and IP and will soon be positioned to enter into manufacturing and licensing agreements.

Technology : Nanomedecine


Manhattan Scientifics acquired Senior Scientific, LLC in 2011 and quickly began the cooperative work to commercialize its nanomedicine cancer detection technology. In 2017 Manhattan Scientifics spun out the cancer project as Imagionbiosystems.com.

Latest news & media

Imagion Biosystems First-in-Human Study Update: First Patient Enrolled

MELBOURNE—Imagion Biosystems Limited(ASX:IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to announce that the first patient has been enrolled in the MagSense® HER2 breast cancer Phase I first-in-human study. Full story
May 26, 2021

MHTX Stock Chart Mimics That of Its Largest Investment to Date: Imagion Biosystems

NEW YORK--Manhattan Scientifics Inc. (OTCQB: MHTX) invested $30 million and a 10-year effort to commercialize the Imagion Biosystems (IBX: AX) super early, non- invasive, non-radioactive Cancer diagnostic, now “partnered” with MD Anderson Cancer Center, Houston. The company is awaiting regulatory approval to initiate human cancer trials. Full story
March 11, 2021

Robert Proulx from Imagion Biosystems (IBX) | CEO Masterclass

Peter Switzer is joined by the CEO of medical imaging company Imagion Biosystems (IBX), Robert Proulx. Full video
March 2020

Bob Proulx at NobleCon12

This video captures Senior Scientific COO Bob Proulx's address to investors at the January 2016 NobleCon meeting, where he presents the unique properties of magnetic relaxometry and explains how it can be used to catch cancer in its earliest stages, when life-saving treatments are most effective. NobleCon is an annual conference attended by investors who want to learn about the most promising new technologies and opportunities. Full video
January 2016